Laura Jean Podewils
Centers for Disease Control and Prevention
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laura Jean Podewils.
International Journal of Geriatric Psychiatry | 2009
Martin Steinberg; Jeannie-Marie S. Leoutsakos; Laura Jean Podewils; Constantine G. Lyketsos
To determine the feasibility and efficacy of a home‐based exercise intervention program to improve the functional performance of patients with Alzheimers Disease (AD).
The Journal of Infectious Diseases | 2005
Laura Jean Podewils; Lynn Antil; Erik Hummelman; Joseph S. Bresee; Umesh D. Parashar; Richard Rheingans
BACKGROUND New rotavirus vaccines may soon be licensed, and decisions regarding implementation of their use will likely be based on the health and economic benefits of vaccination. METHODS We estimated the benefits and cost-effectiveness of rotavirus vaccination in Asia by using published estimates of rotavirus disease incidence, health care expenditures, vaccine coverage rates, and vaccine efficacy. RESULTS Without a rotavirus vaccination program, it is estimated that 171,000 Asian children will die of rotavirus diarrhea, 1.9 million will be hospitalized, and 13.5 million will require an outpatient visit by the time the Asian birth cohort reaches 5 years of age. The medical costs associated with these events are approximately 191 million US dollars; however, the total burden would be higher with the inclusion of such societal costs as lost productivity. A universal rotavirus vaccination program could avert approximately 109,000 deaths, 1.4 million hospitalizations, and 7.7 million outpatient visits among these children. CONCLUSIONS A rotavirus vaccine could be cost-effective, depending on the income level of the country, the price of the vaccine, and the cost-effectiveness standard that is used. Decisions regarding implementation of vaccine use should be based not only on whether the intervention provides a cost savings but, also, on the value of preventing rotavirus disease-associated morbidity and mortality, particularly in countries with a low income level (according to 2004 World Bank criteria for the classification of countries into income groups on the basis of per capita gross national income) where the disease burden is great.
The Journal of Infectious Diseases | 2009
Richard Rheingans; Lynn Antil; Robert Dreibelbis; Laura Jean Podewils; Joseph S. Bresee; Umesh D. Parashar
BACKGROUND Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evaluated the economic burden of rotavirus and the cost-effectiveness of vaccination from the health care perspective. METHODS Estimates were based on existing epidemiological data, cost estimates, vaccine coverage, and efficacy data, as well as hypothetical vaccine prices. Outcome measures included health care and societal costs of rotavirus and benefits and incremental cost-effectiveness ratio of vaccination. Sensitivity analyses evaluated the impact of estimate uncertainty. RESULTS Treatment costs increased with income level, and health burden decreased; however, burden varied across regions. On the basis of current vaccination coverage and timing, rotavirus vaccination would annually prevent 228,000 deaths, 13.7 million hospital visits, and 8.7 million disability-adjusted life-years, saving
Seminars in Pediatric Infectious Diseases | 2004
Laura Jean Podewils; Eric D. Mintz; James P. Nataro; Umesh D. Parashar
188 million in treatment costs and
Clinical Infectious Diseases | 2005
Laura Jean Podewils; Laura A. Liedtke; L. Clifford McDonald; Jeffrey C. Hageman; Larry J. Strausbaugh; Thea Kølsen Fischer; Daniel B. Jernigan; Timothy M. Uyeki; Matthew J. Kuehnert
243 million in societal costs. At
PLOS Medicine | 2008
Frank Cobelens; Einar Heldal; Michael E. Kimerling; Carole D. Mitnick; Laura Jean Podewils; Hans L. Rieder; Karin Weyer; Matteo Zignol
5 per dose, the incremental cost-effectiveness ratio in low-, lower-middle-, and upper-middle-income countries was
Diagnostic Microbiology and Infectious Disease | 2008
La-ong Srisuwanvilai; Patama Monkongdee; Laura Jean Podewils; Keerataya Ngamlert; Vallerut Pobkeeree; Panitchaya Puripokai; Photjanart Kanjanamongkolsiri; Wonchat Subhachaturas; Pasakorn Akarasewi; Charles D. Wells; Jordan W. Tappero; Jay K. Varma
88,
Pediatric Infectious Disease Journal | 2011
Douglas H. Esposito; Robert C. Holman; Dana L. Haberling; Jacqueline E. Tate; Laura Jean Podewils; Roger I. Glass; Umesh D. Parashar
291, and
PLOS ONE | 2013
Laura Jean Podewils; Maria Tarcela Gler; M. I D Quelapio; Michael P. Chen
329 per disability-adjusted life-year averted, respectively, and
BMC Public Health | 2012
Liza Ellen Bronner; Laura Jean Podewils; Annatjie Peters; Pushpakanthi Somnath; Lorna Nshuti; Martie van der Walt; Lerole David Mametja
3,015,